These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28013235)

  • 1. Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study.
    Kim P; Jia P; Zhao Z
    Brief Bioinform; 2018 May; 19(3):450-460. PubMed ID: 28013235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROS1 fusions in cancer: a review.
    Uguen A; De Braekeleer M
    Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
    Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
    PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinase domain activation through gene rearrangement in multiple myeloma.
    Morgan GJ; He J; Tytarenko R; Patel P; Stephens OW; Zhong S; Deshpande S; Bauer M; Weinhold N; Schinke C; Rasche L; Bailey M; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Zangari M; van Rhee F; Mughal T; Davies FE; Walker BA
    Leukemia; 2018 Nov; 32(11):2435-2444. PubMed ID: 29654269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Bastos AU; de Jesus AC; Cerutti JM
    Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.
    Saito M; Shimada Y; Shiraishi K; Sakamoto H; Tsuta K; Totsuka H; Chiku S; Ichikawa H; Kato M; Watanabe S; Yoshida T; Yokota J; Kohno T
    Cancer Res; 2015 Jun; 75(11):2264-71. PubMed ID: 25855381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.
    Cerrato A; Visconti R; Celetti A
    Mol Cancer; 2018 Feb; 17(1):46. PubMed ID: 29455670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
    Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
    Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
    Gao Q; Liang WW; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao WW; Reynolds SM; Wyczalkowski MA; Yao L; Yu L; Sun SQ; ; ; Chen K; Lazar AJ; Fields RC; Wendl MC; Van Tine BA; Vij R; Chen F; Nykter M; Shmulevich I; Ding L
    Cell Rep; 2018 Apr; 23(1):227-238.e3. PubMed ID: 29617662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.
    Lu H; Villafane N; Dogruluk T; Grzeskowiak CL; Kong K; Tsang YH; Zagorodna O; Pantazi A; Yang L; Neill NJ; Kim YW; Creighton CJ; Verhaak RG; Mills GB; Park PJ; Kucherlapati R; Scott KL
    Cancer Res; 2017 Jul; 77(13):3502-3512. PubMed ID: 28512244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.
    Vaughn CP; Costa JL; Feilotter HE; Petraroli R; Bagai V; Rachiglio AM; Marino FZ; Tops B; Kurth HM; Sakai K; Mafficini A; Bastien RRL; Reiman A; Le Corre D; Boag A; Crocker S; Bihl M; Hirschmann A; Scarpa A; Machado JC; Blons H; Sheils O; Bramlett K; Ligtenberg MJL; Cree IA; Normanno N; Nishio K; Laurent-Puig P
    BMC Cancer; 2018 Aug; 18(1):828. PubMed ID: 30115026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel ALK fusion partners in lung cancer.
    Iyevleva AG; Raskin GA; Tiurin VI; Sokolenko AP; Mitiushkina NV; Aleksakhina SN; Garifullina AR; Strelkova TN; Merkulov VO; Ivantsov AO; Kuligina ESh; Pozharisski KM; Togo AV; Imyanitov EN
    Cancer Lett; 2015 Jun; 362(1):116-21. PubMed ID: 25813404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.